Active	Status	Sponsor type	Region	Phase	Filter
12 Active 1 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shu, Qiang
NCT02837978: The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment	Completed	4	150	RoW	Tacrolimus, FK506, MTX, methotrexate	Qiang Shu	Arthritis, Rheumatoid	09/22	12/22
SMART, NCT06722586: Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia	Recruiting	3	84	RoW	Sirolimus, Rapamycin, mTOR inhibitor, Placebo	Peking University First Hospital, North China Pharmaceutical Co.,Ltd	Antiphospholipid (aPL)-positive, Thrombocytopaenia	12/27	12/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.	Recruiting	2/3	240	Europe, Canada, Japan, US, RoW	EFG PH20 SC, PBO	argenx, argenx BV	Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome	12/26	02/27
NCT05614531: Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1	Enrolling by invitation	1/2	12	RoW	EXG001-307 injection	Hangzhou Jiayin Biotech Ltd	Spinal Muscular Atrophy Type I	08/25	08/25
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus	Completed	1	92	RoW	Telitacicept, RC18, standard therapy	RemeGen Co., Ltd.	Systemic Lupus Erythematosus	10/23	11/23
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus	Recruiting	1	48	RoW	SG301 SC Injection, SG301 SC Placebo	Hangzhou Sumgen Biotech Co., Ltd.	Systemic Lupus Erythematosus (SLE)	05/25	10/25
VGM-R02b-101, NCT06217861: A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b	Recruiting	1	12	RoW	VGM-R02b, rAAV9-GCDH	Shanghai Vitalgen BioPharma Co., Ltd.	Glutaric Acidemia Type I, Glutaric Aciduria Type I	08/26	08/26
CAPSTONE, NCT05230017: Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks	Recruiting	N/A	2000	RoW		Peking Union Medical College Hospital	Anti Phospholipid Syndrome	12/26	12/26
Yang, Rulai
VGM-R02b-101, NCT06217861: A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b	Recruiting	1	12	RoW	VGM-R02b, rAAV9-GCDH	Shanghai Vitalgen BioPharma Co., Ltd.	Glutaric Acidemia Type I, Glutaric Aciduria Type I	08/26	08/26
Dong, Guanping
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty	Recruiting	3	93	US, RoW	Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide	Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd.	Puberty; Precocious, Central	11/25	06/26
VGM-R02b-101, NCT06217861: A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b	Recruiting	1	12	RoW	VGM-R02b, rAAV9-GCDH	Shanghai Vitalgen BioPharma Co., Ltd.	Glutaric Acidemia Type I, Glutaric Aciduria Type I	08/26	08/26
Wang, Xianfeng
VGM-R02b-101, NCT06217861: A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b	Recruiting	1	12	RoW	VGM-R02b, rAAV9-GCDH	Shanghai Vitalgen BioPharma Co., Ltd.	Glutaric Acidemia Type I, Glutaric Aciduria Type I	08/26	08/26